Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Invested Capital (2022 - 2025)

TriSalus Life Sciences' Invested Capital history spans 4 years, with the latest figure at -$815000.0 for Q4 2025.

  • For Q4 2025, Invested Capital rose 78.61% year-over-year to -$815000.0; the TTM value through Dec 2025 reached -$815000.0, up 78.61%, while the annual FY2025 figure was -$815000.0, 78.61% up from the prior year.
  • Invested Capital reached -$815000.0 in Q4 2025 per TLSIW's latest filing, down from $6.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $12.9 million in Q2 2025 to a low of -$188.4 million in Q2 2023.
  • Average Invested Capital over 4 years is -$63.3 million, with a median of -$15.5 million recorded in 2023.
  • Peak YoY movement for Invested Capital: plummeted 85.0% in 2024, then soared 423.13% in 2025.
  • A 4-year view of Invested Capital shows it stood at -$161.3 million in 2022, then surged by 83.22% to -$27.1 million in 2023, then skyrocketed by 85.92% to -$3.8 million in 2024, then surged by 78.61% to -$815000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Invested Capital are -$815000.0 (Q4 2025), $6.0 million (Q3 2025), and $12.9 million (Q2 2025).